Interestingly, our data showed that CAFs exposed to the treatment with the PPARγ agonist BRL acquired a phenotype characterized by a decreased expression of α-SMA/vimentin and CXCR4 together with a reduced migratory capability, all features that may negatively impact breast tumor progression. This evidence concerns the gene CXCR4 and breast neoplasm.